Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.
Journal: Lancet (London, England)
Published: September 08, 2025
Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study.
Journal: EClinicalMedicine
Published: February 10, 2023
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.
Journal: The American journal of gastroenterology
Published: January 30, 2021
Education and training of clinical and translational study investigators and research coordinators: A competency-based approach.
Journal: Journal of clinical and translational science
Published: May 10, 2016
Enhancing Clinical Research Professionals' Training and Qualifications (ECRPTQ): Recommendations for Good Clinical Practice (GCP) training for investigators and study coordinators.
Journal: Journal of clinical and translational science
Published: May 10, 2016
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.
Journal: European journal of gastroenterology & hepatology
Published: June 06, 2014
Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C.
Journal: Journal of viral hepatitis
Published: June 19, 2012
Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C.
Journal: Journal of viral hepatitis
Published: May 11, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026